Launch of New Services, Acquisitions, Investments, New Research Facilities and Pending FDA Approvals - Research Report on UnitedHealth, Hi-Tech, Thermo Fisher, Covidien, and Actavis

NEW YORK, August 30, 2013 /PRNewswire/ --

Today, Analysts' Corner announced new research reports highlighting UnitedHealth Group Inc. (NYSE: UNH), Hi-Tech Pharmacal Co. (NASDAQ: HITK), Thermo Fisher Scientific Inc. (NYSE: TMO), Covidien plc (NYSE: COV), and Actavis Inc. (NYSE: ACT). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below.

UnitedHealth Group Inc. Research Report

On August 20, 2013, UnitedHealthcare, a business segment of UnitedHealth Group Inc., introduced myClaims Manager, a secure, online electronic bill payment service that enables customers to pay their medical bills and manage health care claims and related expenses from one location. According to the UnitedHealthcare, the new service enables consumers to pay medical bills electronically by entering their credit card, debit card, health savings account, or bank account information, adding convenience for consumers while helping health care providers get paid faster and easier. The online system is available to UnitedHealthcare employer customers of all sizes and to their employees. The Full Research Report on UnitedHealth Group Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.analystscorner.com/r/full_research_report/73e5_UNH]

--

Hi-Tech Pharmacal Co. Research Report

On August 27, 2013, Hi-Tech Pharmacal Co. (Hi-Tech) and Akorn, Inc. (Akorn) announced that they have entered into a definitive agreement under which Akorn will acquire Hi-Tech for $640 million in cash or $43.50 per share. Hi-Tech stated that this price represents a 23.5% premium over its closing price on August 26, 2013. According to Hi-Tech, the combined company is expected to have annual revenues in excess of $500 million and the transaction is expected to be accretive to Akorn's non-GAAP adjusted EPS immediately upon closing. Hi-Tech's CEO, David Seltzer, said, "The combined portfolio of marketed products and products in development offer a very unique platform with great growth potential. We are very pleased to be joining forces with Akorn and their strong management team led by Raj Rai." The Full Research Report on Hi-Tech Pharmacal Co. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.analystscorner.com/r/full_research_report/5e18_HITK]

--

Thermo Fisher Scientific Inc. Research Report

On August 26, 2013, Thermo Fisher Scientific Inc. (Thermo Fisher) announced an investment in STEM education (science, technology, engineering, and math) that will allocate nearly $0.7 million per year to support scholarships at some of the world's most prestigious universities. The Company stated that it has established a competitive program to provide financial assistance to students who are pursuing an undergraduate degree or equivalent in a STEM field at any of these five premier institutions globally: Massachusetts Institute of Technology; University of Wisconsin-Madison; University of California-Berkeley; Imperial College London and Fudan University in Shanghai. Thermo Fisher said that the STEM Scholarship Program will offer funding to 44 students annually, and that the Company expects to grow this program to full maturity in four years with 164 students. The Full Research Report on Thermo Fisher Scientific Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.analystscorner.com/r/full_research_report/45ed_TMO]

--

Covidien plc Research Report

On August 27, 2013, Covidien plc (Covidien) announced the opening of the Covidien Center of Innovation Korea (CCI Korea), the Company's first R&D training and education center in Korea. The Company reported that with an investment of $21 million over a three year period, CCI Korea is a high-tech medical training center focused on raising awareness of various disease states and providing opportunities for advancing healthcare professionals' capabilities by creating access to a full range of Covidien's medical devices. Brian D. King, President, Emerging Markets, Covidien, said, "Korea is a key market in our global strategy, and this investment is a reflection of our commitment to partnering with Korean healthcare professionals." The Full Research Report on Covidien plc - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.analystscorner.com/r/full_research_report/a14c_COV]

--

Actavis Inc. Research Report

On August 27, 2013, Actavis Inc. (Actavis) confirmed that it has filed an Abbreviated New Drug Application (ANDA) with the US Food and Drug Administration (FDA), seeking approval to market Prednisone Delayed-release Tablets, 1mg, 2mg, and 5mg. The Company stated that its ANDA products are generic versions of Horizon Pharma's Rayos. Further, Actavis stated that on August 26, 2013, Horizon Pharma AG and Jagotec AG filed a suit against the Company in the U.S. District Court for the District of New Jersey seeking to prevent Actavis from commercializing its ANDA products prior to the expiration of certain U.S. patents. Actavis said that the lawsuit was filed under the provisions of the Hatch-Waxman Act, resulting in a stay of final FDA approval of Actavis' ANDA for up to 30 months from the date the plaintiffs received notice of Actavis' ANDA filing, or until final resolution of the matter before the court, whichever occurs sooner, subject to any other exclusivities. The Company believes that it is the first applicant to file an ANDA for the generic version of Rayos, and should its ANDA be approved, it may be entitled to 180 days of market exclusivity. The Full Research Report on Actavis Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.analystscorner.com/r/full_research_report/4997_ACT]

----

EDITOR NOTES:

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Equity News Network. An outsourced research services provider has, through Chartered Financial Analysts, only reviewed the information provided by Equity News Network in this article or report according to the Procedures outlined by Equity News Network. Equity News Network is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.

NOT FINANCIAL ADVICE

Equity News Network makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Equity News Network is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Equity News Network whatsoever for any direct, indirect or consequential loss arising from the use of this document. Equity News Network expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Equity News Network does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

AnalystsCorner.com

SOURCE Analysts' Corner